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ECONOMIC EVALUATION OF TRABECTEDIN IN THE TREATMENT  
OF METASTATIC SOFT-TISSUE SARCOMA (MSTS) IN THE  
FINNISH SETTING
Soini EJ1, García San Andrés B2, Joensuu T3
1ESiOR Oy, Kuopio, Finland, 2PharmaMar, Madrid, Spain, 3International Comprehensive 
Cancer Centre Docrates, Helsinki, Finland
OBJECTIVES: To compare the cost-effectiveness and cost-utility of a new orphan 
drug trabectedin, Yondelis, against various end-stage treatments (EST) following the 
failure with two chemotherapy agents (anthracycline and ifosfamide) that are approved 
for the ﬁrst line treatment of mSTS in Finland. METHODS: An Excel-based Markov 
model with trabectedin and no trabectedin arms is used in the evaluation. Analyses 
are performed from a societal lifetime perspective (production losses and VAT 
excluded) using a probabilistic (second-order Monte Carlo) approach. The cost-
 effectiveness is evaluated on the basis of cost-effectiveness acceptability frontier, incre-
mental cost per life-year gained (LYG) and quality-adjusted life-years (QALY) gained. 
Included resources are drugs, mSTS treatments, adverse event treatments and travel-
ling. In the base case analysis, 33% of patients are assumed to receive EST (67% 
etoposide, 33% dacarbazine). The effectiveness of drugs is based on the indirect 
comparison of EORTC Soft Tissue and Bone Sarcoma Group (Nielsen 2000; van          
Oosterom 2002) and ET743-STS-201 trial results. Finnish resources and costs from        
year 2006 are taken, and both costs and outcomes are discounted with 5% per annum. 
RESULTS: Trabectedin is associated with incremental 1.14 LYGs, a37,875 additional 
costs and a33,099 cost per LYG compared to EST. With the willingness to pay of 
a50,000 per LYG, trabectedin has over 98% probability of being cost-effective. When 
the quality of remaining life time is taken into account using assumptions, the incre-
mental cost per QALY range between a38,801–a46,425. The results are robust 
according to multiple sensitivity analyses (including also comparisons against other 
ESTs: etoposide or dacarbazine monotherapy; doxorubicin, ifosfamide, mesna and 
dacarbazine (IADIC); ifosfamide, mesna, etoposide, fenobarbital and growth hormone 
(IE); and ifosfamide, mesna, etoposide and methotrexate (IMVP-a6)). CONCLU-
SIONS: Trabectedin is a valuable addition for the treatment of mSTS. The cost-
 effectiveness of trabectedin is comparable or even superior to many other cancer drugs 
for non-orphan conditions.
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EXPLORING THE COST-EFFECTIVENESS OF A SMOKING-CESSATION 
PROGRAM ENHANCED WITH INDIVIDUAL GENETIC FEEDBACK ON 
LUNG CANCER RISK
Gordon LG1, Hirst NG1, Young RP2, Brown PM3
1Queensland Institute of Medical Research, Brisbane, Australia, 2Auckland Hospital, Auckland, 
New Zealand, 3The University of Auckland, Auckland, New Zealand
OBJECTIVES: Several genetic characteristics are implicated in the onset of lung cancer 
and the smoking-gene interaction means that some smokers are at greater risk of 
developing lung cancer than others. The purpose of this study was to explore the 
potential cost-effectiveness of offering smokers a genetic test designed to provide 
feedback regarding their individual risk of developing lung cancer to motivate smoking 
cessation. METHODS: Two strategies were modelled; heavy-smoking individuals 
aged 50 years either received or did not receive a genetic test within the course of a 
usual smoking-cessation intervention comprising nicotine replacement therapy (NRT) 
and counselling. A Markov model was constructed using evidence from published 
randomized controlled trials and meta-analyses for estimates on 12-month quit rates 
and long-term relapse rates. Recent epidemiological data were used for estimates on 
the risk of developing lung cancer stratiﬁed by time since quitting and heavy/light 
smoking patterns. Scenario analyses, one-way and probabilistic sensitivity analyses 
were used to explore uncertainty. RESULTS: The discounted incremental costs for the 
genetic testing strategy were AU$299 and corresponding quality-adjusted life years 
(QALYs) were 0.0109 producing an incremental cost per QALY of AUS$34,687 (95% 
CI $12,483, $87,734). At a willingness-to-pay of AU$20,000 per QALY gained, the 
genetic testing strategy needs to have a minimum 12-month quit rate of 12.4% or the 
relapse rate 12% lower to demonstrate cost-effective equivalence to NRT and counsel-
ling alone. The probability that adding a genetic test to the usual smoking-cessation 
intervention is cost-effective was 20.6%. CONCLUSIONS: Very small differences in 
costs and QALYs were found between the two options over a period of 35 years. The 
ﬁndings were sensitive to small changes in critical variables such as the 12-month quit 
rates and relapse rates. Further research on smoking-cessation quit rates following 
genetic testing is needed to inform cost-utility analyses.
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COST-EFFECTIVENESS OF HPV VACCINATION—AN OVERVIEW ON 
INTERNATIONAL STUDY RESULTS
Damm O, Greiner W
University of Bielefeld, Bielefeld, Germany
OBJECTIVES: In multiple clinical trails the efﬁcacy of HPV vaccination against 
virus-speciﬁc pre-stages of cervical cancer was veriﬁed. Because decision-makers 
are increasingly interested in information on the cost-value ratios of new interventions 
we conducted a systematic review to summarize current international evidence con-
cerning the long-term cost-effectiveness of HPV vaccination. METHODS: To ascertain 
studies published in the peer-reviewed medical and health-economic literature a 
MEDLINE-based literature research was conducted in June 2009. Furthermore the 
web presences of international HTA organisations were screened for relevant publica-
tions. Language was limited to English and German. Finally 29 health-economic 
publications which refer to 26 modelling studies were included in the review. 
RESULTS: Within the study results there is signiﬁcant variation due to the heterogene-
ity of methodical backgrounds and input parameters. Base case results (including 
direct cost for vaccination of female adolescences  screening vs. solely screening) 
vary from a3,000 to a40,000 per QALY and from a9,000 to a65,000 per LYG. Due 
to the consideration of herd immunity the application of transmission models fre-
quently resulted in lower cost-effectiveness ratios than static cohort models. Assump-
tions about the duration of protection can be considered as the major inﬂuencing 
factor within all studies. CONCLUSIONS: Regarding the long-term consequences 
of HPV vaccination, international studies suggest that HPV vaccination is cost- 
effective when assuming a lifelong protection. Because modelling results signi-
ﬁcantly depend on the duration of immunization which is associated with a high 
degree of uncertainty it is not possible to draw a ﬁnal conclusion regarding the cost-
effectiveness of HPV vaccination based on the current health-economic evidence. 
Hence, risk-sharing-agreements between third-party payers and manufacturers 
would pose an option to balance the consequences of uncertainty towards the duration 
of protection on cost-effectiveness.
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PHARMAECONOMIC EVALUATION OF THE USE OF PROLONGED 
LIBERATION HIDROMORFONE IN THE MANAGEMENT OF MODERATE 
TO SEVERE CHRONIC PAIN FOR CANCER AT AN INSTITUTIONAL 
LEVEL IN MEXICO
Vargas J1, Tenorio C2, Martínez J3, Soto-Molina H4, Castillejos Zenteno C4
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OBJECTIVES: To demonstrate that the use of prolonged liberation hidromorfone 
(PLHM) in the management of moderate to severe chronic pain for cancer (MCCP) 
is cost-effective and demonstrates cost-utility compared with prolonged liberation 
morphine (LM) from the perspective of the Instituto Mexicano del Seguro Social 
(IMSS). METHODS: A decision tree was built with a one year time horizon and vali-
dated by an expert panel (EP). An assumption in the model is that, if any of the initial 
treatments fail, fentanil would be used. The effectiveness data (deﬁned as quality of 
life related to health—QLH) utility (deﬁned in Qalys), and adverse events (AE) of the 
medications were obtained from the literature with a systematic revision. The total 
cost was integrated with the cost of medications (average dose required for the sus-
tained efﬁcacy and extended use in a year) and attention of the AE for the use of the 
opioids, through the EP. The unitary costs were obtained from the IMSS. An incre-
mental analysis of cost and results in health was realized, to compare PLHM and LM. 
A sensitivity analysis was also accomplished (deterministic and probabilistic) as well 
as a budgetary impact analysis. RESULTS: Patients with MCCP that used PLHM 
obtain more QLH (6.06 vs 4.44) and Qalys (0.5620 vs 0.5324) than those that used 
LM. In addition, patients using PLHM would show less AE than those using lM. 
PLHM resulted as the alternative with less unitary annual average total cost than LM: 
$46,242.59 and $50,074.04, respectively. PLHM is a dominant option compared with 
LM. Sensitivity analysis showed robustness in the results. The budgetary impact shows 
saving of more than 99 million pesos a year using PLHM instead of LM in the health 
public institutions. CONCLUSIONS: PLHM is an effective option that can be cost-
saving in the treatment of MCCP in Mexico.
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COST-EFFECTIVENESS OF RITUXIMAB IN PREVIOUSLY UNTREATED 
PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE  
DUTCH SETTING
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OBJECTIVES: To determine the cost-effectiveness of rituximab (RTX) added to ﬁrst 
line chemotherapy in patients with chronic lymphocytic leukemia (CLL) in the 
 Netherlands (NL). Results were used to identify parameters to explore in a local 
population-based haematological registry (PHAROS). METHODS: A three health 
state transition cost-effectiveness model was developed to evaluate the costs and clini-
cal outcomes of treatment with either chemotherapy (ﬂudarabine cyclophosphamide; 
FC) or RTX  FC. Patient level data were obtained from the pivotal study CLL-8 
(Hallek et al., 2008). As chlorambucil (C) is frequently used in NL, an indirect com-
parison of RTX-FC vs. C was included. Patients commenced in the progression-free 
(PFS) state with transitions to progressive disease or death. PFS and overall survival 
(OS) data were extrapolated over 15 years with monthly cycles. Utility values origi-
nated from a CLL HTA study using the EQ-5D York Tariff. The perspective was 
societal and direct costs were obtained from ofﬁcial Dutch price sources(Farmacother
apeutisch Kompas, Oostenbrink et al. 2004). Effects and costs were discounted at       
1.5% and 4% p.a. respectively (Dutch pharmaco-economic guidelines). RESULTS: 
RTX-FC was more effective than FC or C. RTX-FC treatment resulted in 1 QALY 
and 1.23 life years gained (LYG) vs. FC. With RTX-FC costs being a 16,317 higher, 
this resulted in ICERs of a16,242/QALY and a13,217/LYG vs. FC. RTX-FC vs. C 
resulted in 2.14 QALY gain and 2.64 LYG leading to ICERs of a9813/QALY and 
a7953/LYG. Results were most sensitive to the time horizon and utility values. 
However, in all cases RTX-FC treatment was cost-effective. OS, resource use and 
quality of life will be collected prospectively in PHAROS with the aim of conﬁrming 
these results. CONCLUSIONS: RXT-FC therapy in NL is cost-effective and represents 
good value for money. Real life data obtained from PHAROS will be used to re-
 evaluate these outcomes in 3-years time.
